- Home
- BHRB vs PHAT Comparison
BHRB vs PHAT Comparison
Compare BHRB & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHRB
- PHAT
- Stock Information
- Founded
- BHRB 1852
- PHAT 2018
- Country
- BHRB United States
- PHAT United States
- Employees
- BHRB N/A
- PHAT N/A
- Industry
- BHRB Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- BHRB Finance
- PHAT Health Care
- Exchange
- BHRB Nasdaq
- PHAT Nasdaq
- Market Cap
- BHRB 843.3M
- PHAT 727.5M
- IPO Year
- BHRB N/A
- PHAT 2019
- Fundamental
- Price
- BHRB $63.02
- PHAT $8.91
- Analyst Decision
- BHRB Strong Buy
- PHAT Strong Buy
- Analyst Count
- BHRB 2
- PHAT 5
- Target Price
- BHRB $73.00
- PHAT $16.40
- AVG Volume (30 Days)
- BHRB 73.1K
- PHAT 4.9M
- Earning Date
- BHRB 07-25-2025
- PHAT 08-07-2025
- Dividend Yield
- BHRB 3.49%
- PHAT N/A
- EPS Growth
- BHRB 46.75
- PHAT N/A
- EPS
- BHRB 3.98
- PHAT N/A
- Revenue
- BHRB $288,679,000.00
- PHAT $81,859,000.00
- Revenue This Year
- BHRB $51.95
- PHAT $195.45
- Revenue Next Year
- BHRB $4.56
- PHAT $106.76
- P/E Ratio
- BHRB $15.84
- PHAT N/A
- Revenue Growth
- BHRB 168.50
- PHAT 3055.70
- 52 Week Low
- BHRB $47.28
- PHAT $2.21
- 52 Week High
- BHRB $75.32
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- BHRB 72.05
- PHAT 57.30
- Support Level
- BHRB $59.19
- PHAT $8.72
- Resistance Level
- BHRB $59.45
- PHAT $10.13
- Average True Range (ATR)
- BHRB 1.63
- PHAT 0.87
- MACD
- BHRB 0.47
- PHAT -0.28
- Stochastic Oscillator
- BHRB 97.19
- PHAT 7.42
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.